MHLW Grants NHI Listing To 23 Generic Makers For Daiichi Sankyo’s Levofloxacin
This article was originally published in PharmAsia News
Executive SummaryThe Ministry of Health, Labor and Welfare May 15 listed 318 generic drugs for the national health insurance price listing, including 23 companies listed for Daiichi Sankyo's antibacterial Cravit (levofloxacin). Those generic companies include Sawai Pharmaceutical, Nichi-Iko, Taiyo and Towa Pharmaceutical. The NHI also included 39 generic drugs for Daiichi Sankyo's hypertension drug Acecol (temocapril). Japan's major generic drug makers such as Sawai had 22 drugs listed, Nichi-Iko had 23 drugs, Taiyo had 17, Nipro Pharma had 15 and Towa got 14 drugs listed. The generic drug NHI price listing is conducted twice a year in Japan, in July and November. The July date this year was moved up to May. (Click here for more - Japanese language
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.